Double-blind phase III trial of adjuvant chemotherapy withand without bevacizumab in patients with lymph node-positiveand high-risk lymph node-negative breast cancer (E5103)

Kathy D. Miller, Anne O'Neill, William Gradishar, Timothy J. Hobday, Lori J. Goldstein, Ingrid A. Mayer, Stuart Bloom, Adam M. Brufsky, Amye J. Tevaarwerk, Joseph A. Sparano, Nguyet Anh Le-Lindqwister, Carolyn B. Hendricks, Donald W. Northfelt, Chau T. Dang, George W. Sledge

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Double-blind phase III trial of adjuvant chemotherapy withand without bevacizumab in patients with lymph node-positiveand high-risk lymph node-negative breast cancer (E5103)'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science